Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals (NASDAQ: KALV) granted inducement options for 43,000 shares to five new employees on September 1, 2021. The options have an exercise price of $20.76 per share, matching the stock's closing price on the grant date. Vesting occurs gradually over four years. KalVista is focused on developing small molecule protease inhibitors for unmet medical needs, notably in hereditary angioedema and diabetic macular edema. The company is advancing multiple clinical trials, including KVD900 for HAE.
KalVista Pharmaceuticals (NASDAQ: KALV) announced significant progress in the Phase 2 clinical trial (KOMPLETE) for KVD824, targeting oral prophylactic treatment of hereditary angioedema (HAE). Regulatory approvals have been obtained in Canada, Australia, and the UK, with patient enrollment expected to commence this quarter. The trial will evaluate various doses of KVD824 against a placebo over 12 weeks. So far, 121 patients have been treated with KVD824, demonstrating a favorable safety profile.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of 20,000 inducement stock options to four newly-hired employees as part of their employment agreement on August 3, 2021. The options have an exercise price of $20.65 per share, aligning with the closing price on the grant date. Vesting occurs in stages, with one-fourth vesting after one year and the rest monthly over three years. KalVista focuses on developing small molecule protease inhibitors for serious diseases, including hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (KALV) released its operational update and financial results for the fiscal year ending April 30, 2021. Notable progress includes positive Phase 2 results for KVD900, with a Phase 3 program review set with the FDA. However, no revenue was reported for the year, compared to $12.7 million in the previous year, due to the expiration of the Merck Option Agreement. The net loss increased to $46.2 million, primarily from R&D spending and lack of revenue. Cash reserves improved to $248.9 million after a successful public offering in February 2021.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented significant data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress on its oral drug candidates. The late-breaking poster showcased Phase 2 results for KVD900, showing that it halted attack progression and accelerated symptom resolution in hereditary angioedema (HAE) patients. Additionally, posters addressed the prevalence and management challenges of normal C1-INH HAE in the US. KVD900 demonstrated a favorable safety profile, positioning it as a potential key therapy for HAE patients.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced multiple abstracts accepted at the European Academy of Allergy and Clinical Immunology Congress, July 10-12, 2021. Key highlights include:
- KVD900: A phase 2 trial showed it significantly slows hereditary angioedema (HAE) attacks.
- Nationwide surveys on HAE treatment prevalence and management.
- Research on oral Factor XIIa inhibitor KVD998052 for acute respiratory distress syndrome (ARDS).
The company focuses on developing small molecule protease inhibitors for unmet medical needs.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the presentation of clinical data for KVD900 at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. KVD900 demonstrates rapid plasma kallikrein inhibition and significantly improves symptoms of hereditary angioedema (HAE) attacks within 24 hours. The Phase 2 trial involved 68 patients, with 53 successfully completing it. KVD900 has received FDA Fast Track designation and EMA approval for its Pediatric Investigational Plan, indicating promising regulatory support for its development.
KalVista Pharmaceuticals (NASDAQ:KALV) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET. A live webcast is available at www.kalvista.com, with an audio archive accessible for 30 days post-event.
KalVista focuses on small molecule protease inhibitors for unmet medical needs, particularly targeting hereditary angioedema and diabetic macular edema. Their candidate KVD900, aimed at acute HAE attacks, completed a significant Phase 2 trial in February 2021.
KalVista Pharmaceuticals (NASDAQ: KALV) announces KVD900's acceptance for oral presentation at the 12th C1-Inhibitor Deficiency & Angioedema Workshop from June 3-6, 2021. The presentation will detail a Phase 2 trial's findings, showcasing KVD900's pharmacokinetic and pharmacodynamic profile and its effectiveness in treating hereditary angioedema (HAE) attacks. This highlights KalVista's ongoing commitment to addressing unmet needs in HAE treatment through innovative therapies.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Dr. Paul K. Audhya as Chief Medical Officer. Dr. Audhya brings over 20 years of experience in clinical development and global medical affairs across various therapeutic areas. This strategic addition aims to enhance the company's late-stage drug development and global commercialization efforts, particularly as they advance their oral hereditary angioedema franchise. Dr. Audhya expressed enthusiasm about joining KalVista at a pivotal time for their innovative therapies.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
